{"id":"W4282937497","doi":"10.1158/1538-7445.am2022-ct572","title":"Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nuvo Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Carboplatin; Pemetrexed; Internal medicine; Oncology; Trastuzumab; Tolerability; Durvalumab; Lapatinib; Cancer; Lung cancer; Chemotherapy; Cisplatin; Nivolumab; Breast cancer; Immunotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004363115,0.0005440151,0.001027792,0.001299303,0.0008749074,0.000157835,0.0003041365,0.00009589353,0.0004908875],"category_scores_gemma":[0.0009499247,0.0004289445,0.00005229169,0.002570501,0.000354191,0.0004429766,0.0005361713,0.001928801,0.000001197411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003291398,"about_ca_system_score_gemma":0.003295277,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01401602,"about_ca_topic_score_gemma":0.02958971,"domain_scores_codex":[0.99235,0.001158603,0.0009749005,0.001416461,0.002811296,0.001288704],"domain_scores_gemma":[0.9964027,0.001537935,0.0003436563,0.0005713032,0.0007612181,0.0003831475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07165383,0.01174888,0.4015455,0.005313035,0.0005802676,0.002287626,0.0452652,0.0106651,0.1225555,0.000006693798,0.0005492411,0.3278291],"study_design_scores_gemma":[0.1405373,0.02173313,0.7276769,0.003220845,0.0004225286,0.000080198,0.03596394,0.06361271,0.005565561,0.00004981408,0.00005923107,0.001077894],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849795,0.00529562,0.00005749785,0.0004052626,0.0001038782,0.008754194,0.0001065561,0.00006048592,0.0002370085],"genre_scores_gemma":[0.9902121,0.000935613,0.001439943,0.00005031602,0.00007482236,0.006576986,0.00005183736,0.0001384804,0.0005198473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3267512,"threshold_uncertainty_score":0.9998162,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0972688980441431,"score_gpt":0.4678346401220942,"score_spread":0.3705657420779511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}